Why didn't Baosteel increase its holdings of Haiyun Metal?

Haiyun Metal said that Baosteel Metal's shareholding ratio will be further increased, which will help to further optimize the company's shareholding structure and introduce more resources for the company, thus having a positive impact on the company's business development. Baosteel Metal said that the purpose of this changes in equity is to promote the implementation of the development strategy of "one base and five yuan" of Baowu Group, develop Baosteel's light metal materials and products industry, and promote the sound development of Baosteel's metal business system.

Brief introduction of Baosteel metal co., ltd

Baosteel Metal is one of the wholly-owned subsidiaries of Baosteel Group Corporation. In order to vigorously develop the steel extension processing industry, at the end of 2007, Baosteel Group integrated industrial companies, steel division, automobile trade and wire products to establish Baosteel Metal, which became an important platform for the development of Baosteel's steel extension processing industry. Baosteel Metal is one of the six business segments of Baosteel, and its core business includes steel structure, metal packaging and industrial gas. The products and services of Baosteel's metal steel structure business section cover almost all the application fields of steel structure, and have already had considerable influence in domestic and foreign markets, and achieved certain results.

Overview of Haiyun Metal Company's Stock

Haiyun Company has established and implemented a perfect quality assurance system, and every employee can get good quality awareness and effective work training. All aspects of production technology can be controlled and optimized through Haiyun technology and complete system. In addition, the application of process statistics also ensures high-quality products. The company is equipped with modern analysis and test equipment to ensure accurate and effective data analysis.

Behind Haiyun Metal is Baosteel Metal, a subsidiary of Baosteel Group. Judging from the overall background and investment logic, similar to Xintian Pharmaceutical, it is also funded by Shanghai state-owned assets, and the cost is higher. Although the performance of the same thing began to improve significantly, except for the industry attribute, I basically attributed it to the same essence, the capital attribute. As long as there is capital, the overall result may far exceed a considerable number of stocks. Of course, the capital attributes behind many stocks are different, and we still have to weigh them at the probability level. From the perspective of patients' interests, we should bear the consequences of small probability mistakes and gain potential high probability flexibility.